GlassScriptPhysician profile
Erin Conway
NPI 1558756098
$9,105.56
in general payments reported to CMS, 2019-2025
37 companies · $540 in 2025
The $540 reported for 2025 was more than what 82% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $451 · 2020: $510 · 2021: $328 · 2022: $5,654 · 2023: $318 · 2024: $1,305 · 2025: $540.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,466 · Travel and Lodging: $697.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,465.63 |
| Travel and Lodging | $696.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $5,859.59 | 2022-2024 | |
| Hologic Sales and Service, LLC | $481.94 | 2020-2025 | Acessa Provu System, Coolseal Generator, Myosure Tissue Removal Device |
| Abbvie INC. | $315.73 | 2019-2023 | Lo Loestrin Fe, Orilissa |
| Exeltis, USA INC. | $234.30 | 2020-2025 | Slynd |
| Davol INC. | $224.95 | 2025 | Arista |
| Mayne Pharma Commercial LLC | $207.61 | 2022-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $202.68 | 2019-2025 | |
| Evofem Biosciences, INC. | $167.43 | 2021-2025 | Phexxi, Solosec, Phexx |
| Lupin INC. | $161.90 | 2019-2020 | |
| Daiichi Sankyo INC. | $133.85 | 2020-2023 | Injectafer |
| Sumitomo Pharma America, INC. | $122.56 | 2023-2025 | Myfembree |
| Becton, Dickinson and Company | $117.66 | 2019 | |
| Aspira Women'S Health INC | $90.05 | 2022 | |
| Scynexis, INC. | $88.56 | 2022 | |
| Medtronic USA, INC. | $86.76 | 2019 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $57.58 | 2023-2024 | Veozah, Myrbetriq |
| Organon LLC | $51.09 | 2022-2025 | Nexplanon |
| Therapeuticsmd, INC. | $43.31 | 2020-2022 | |
| Smith+Nephew, INC. | $36.96 | 2023-2024 | Pico 14, Pico |
| Myovant Sciences INC. | $31.85 | 2022 | |
| Millicent US INC | $31.51 | 2020-2025 | Intrarosa |
| Baxter Healthcare | $31.26 | 2025 | Floseal |
| Agile Therapeutics, INC. | $29.83 | 2021 | |
| Pfizer INC. | $29.50 | 2022-2024 | |
| Allergan, INC. | $29.48 | 2019 | |
| Exact Sciences Corporation | $26.92 | 2025 | Cologuard Collection Kit |
| Coopersurgical, INC. | $26.39 | 2019-2021 | |
| Amgen INC. | $25.90 | 2021 | |
| C. R. Bard, INC. & Subsidiaries | $24.95 | 2019 | |
| Dysis Medical, INC. | $23.94 | 2021 | |
| Roche Diagnostics Corporation | $19.90 | 2021 | |
| Sanofi Pasteur INC. | $17.63 | 2022 | |
| Sage Therapeutics, LLC | $16.88 | 2024 | |
| Merck Sharp & Dohme LLC | $14.29 | 2020 | |
| Channel Medsystems, INC. | $14.23 | 2023 | |
| Medicem INC. | $13.59 | 2021 | |
| Alexion Pharmaceuticals, INC. | $13.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erin Conway listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.